Nonfunctioning malignant neuroendocrine tumors of the pancreas

Frederic Eckhauser, P. S. Cheung, A. I. Vinik, W. E. Strodel, R. V. Lloyd, N. W. Thompson

Research output: Contribution to journalArticle

Abstract

The clinical features of eight women and three men with nonfunctioning islet cell carcinoma of the pancreas were reviewed. The mean patient age was 58 years (range 44 to 75 years). Weight loss and abdominal pain were the most frequent presenting symptoms. An abdominal mass was palpable in five patients. At operation regional or distant metastases were present in 82% of patients. Only 18% of patients underwent resection for potential cure. All tumors proved histologically to be neuroendocrine in origin. Immunohistochemical staining showed positive reactivity for neuron-specific enolase and chromogranin in all tumors studied but was negative for insulin, glucagon, and somatostatin. Focal positivity for pancreatic polypeptide was seen in one tumor. Nine patients with unresectable disease at operation were available for follow-up. Mean survival for the entire group was 23 ± 7.2 months (range 4 to 72 months). Survival differences between women and men appeared to favor women but were not statistically significant. Postoperative regional or systemic chemotherapy also had no significant effect on patient survival although two of the longest survivors (36 and 72 months) had received adjunctive chemotherapy. Nonfunctioning islet cell neoplasms are locally aggressive, have a propensity for early metastases, and are rarely resectable for cure. Unlike pancreatic exocrine carcinomas, endocrine malignancies may respond favorably to adjunctive chemotherapy.

Original languageEnglish (US)
Pages (from-to)978-988
Number of pages11
JournalSurgery
Volume100
Issue number6
StatePublished - 1986
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Pancreas
Neoplasms
Drug Therapy
Survival
Islet Cell Carcinoma
Neoplasm Metastasis
Chromogranins
Pancreatic Polypeptide
Phosphopyruvate Hydratase
Somatostatin
Glucagon
Islets of Langerhans
Abdominal Pain
Survivors
Weight Loss
Insulin
Staining and Labeling

ASJC Scopus subject areas

  • Surgery

Cite this

Eckhauser, F., Cheung, P. S., Vinik, A. I., Strodel, W. E., Lloyd, R. V., & Thompson, N. W. (1986). Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery, 100(6), 978-988.

Nonfunctioning malignant neuroendocrine tumors of the pancreas. / Eckhauser, Frederic; Cheung, P. S.; Vinik, A. I.; Strodel, W. E.; Lloyd, R. V.; Thompson, N. W.

In: Surgery, Vol. 100, No. 6, 1986, p. 978-988.

Research output: Contribution to journalArticle

Eckhauser, F, Cheung, PS, Vinik, AI, Strodel, WE, Lloyd, RV & Thompson, NW 1986, 'Nonfunctioning malignant neuroendocrine tumors of the pancreas', Surgery, vol. 100, no. 6, pp. 978-988.
Eckhauser F, Cheung PS, Vinik AI, Strodel WE, Lloyd RV, Thompson NW. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery. 1986;100(6):978-988.
Eckhauser, Frederic ; Cheung, P. S. ; Vinik, A. I. ; Strodel, W. E. ; Lloyd, R. V. ; Thompson, N. W. / Nonfunctioning malignant neuroendocrine tumors of the pancreas. In: Surgery. 1986 ; Vol. 100, No. 6. pp. 978-988.
@article{443496d27a3a4ebb86bef7f604472717,
title = "Nonfunctioning malignant neuroendocrine tumors of the pancreas",
abstract = "The clinical features of eight women and three men with nonfunctioning islet cell carcinoma of the pancreas were reviewed. The mean patient age was 58 years (range 44 to 75 years). Weight loss and abdominal pain were the most frequent presenting symptoms. An abdominal mass was palpable in five patients. At operation regional or distant metastases were present in 82{\%} of patients. Only 18{\%} of patients underwent resection for potential cure. All tumors proved histologically to be neuroendocrine in origin. Immunohistochemical staining showed positive reactivity for neuron-specific enolase and chromogranin in all tumors studied but was negative for insulin, glucagon, and somatostatin. Focal positivity for pancreatic polypeptide was seen in one tumor. Nine patients with unresectable disease at operation were available for follow-up. Mean survival for the entire group was 23 ± 7.2 months (range 4 to 72 months). Survival differences between women and men appeared to favor women but were not statistically significant. Postoperative regional or systemic chemotherapy also had no significant effect on patient survival although two of the longest survivors (36 and 72 months) had received adjunctive chemotherapy. Nonfunctioning islet cell neoplasms are locally aggressive, have a propensity for early metastases, and are rarely resectable for cure. Unlike pancreatic exocrine carcinomas, endocrine malignancies may respond favorably to adjunctive chemotherapy.",
author = "Frederic Eckhauser and Cheung, {P. S.} and Vinik, {A. I.} and Strodel, {W. E.} and Lloyd, {R. V.} and Thompson, {N. W.}",
year = "1986",
language = "English (US)",
volume = "100",
pages = "978--988",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Nonfunctioning malignant neuroendocrine tumors of the pancreas

AU - Eckhauser, Frederic

AU - Cheung, P. S.

AU - Vinik, A. I.

AU - Strodel, W. E.

AU - Lloyd, R. V.

AU - Thompson, N. W.

PY - 1986

Y1 - 1986

N2 - The clinical features of eight women and three men with nonfunctioning islet cell carcinoma of the pancreas were reviewed. The mean patient age was 58 years (range 44 to 75 years). Weight loss and abdominal pain were the most frequent presenting symptoms. An abdominal mass was palpable in five patients. At operation regional or distant metastases were present in 82% of patients. Only 18% of patients underwent resection for potential cure. All tumors proved histologically to be neuroendocrine in origin. Immunohistochemical staining showed positive reactivity for neuron-specific enolase and chromogranin in all tumors studied but was negative for insulin, glucagon, and somatostatin. Focal positivity for pancreatic polypeptide was seen in one tumor. Nine patients with unresectable disease at operation were available for follow-up. Mean survival for the entire group was 23 ± 7.2 months (range 4 to 72 months). Survival differences between women and men appeared to favor women but were not statistically significant. Postoperative regional or systemic chemotherapy also had no significant effect on patient survival although two of the longest survivors (36 and 72 months) had received adjunctive chemotherapy. Nonfunctioning islet cell neoplasms are locally aggressive, have a propensity for early metastases, and are rarely resectable for cure. Unlike pancreatic exocrine carcinomas, endocrine malignancies may respond favorably to adjunctive chemotherapy.

AB - The clinical features of eight women and three men with nonfunctioning islet cell carcinoma of the pancreas were reviewed. The mean patient age was 58 years (range 44 to 75 years). Weight loss and abdominal pain were the most frequent presenting symptoms. An abdominal mass was palpable in five patients. At operation regional or distant metastases were present in 82% of patients. Only 18% of patients underwent resection for potential cure. All tumors proved histologically to be neuroendocrine in origin. Immunohistochemical staining showed positive reactivity for neuron-specific enolase and chromogranin in all tumors studied but was negative for insulin, glucagon, and somatostatin. Focal positivity for pancreatic polypeptide was seen in one tumor. Nine patients with unresectable disease at operation were available for follow-up. Mean survival for the entire group was 23 ± 7.2 months (range 4 to 72 months). Survival differences between women and men appeared to favor women but were not statistically significant. Postoperative regional or systemic chemotherapy also had no significant effect on patient survival although two of the longest survivors (36 and 72 months) had received adjunctive chemotherapy. Nonfunctioning islet cell neoplasms are locally aggressive, have a propensity for early metastases, and are rarely resectable for cure. Unlike pancreatic exocrine carcinomas, endocrine malignancies may respond favorably to adjunctive chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0022896379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022896379&partnerID=8YFLogxK

M3 - Article

C2 - 3024343

AN - SCOPUS:0022896379

VL - 100

SP - 978

EP - 988

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 6

ER -